Boston Partners Increases Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Boston Partners increased its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 57.5% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 400,797 shares of the medical equipment provider's stock after purchasing an additional 146,268 shares during the period. Boston Partners owned 0.58% of Lantheus worth $36,201,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. William Blair Investment Management LLC boosted its position in Lantheus by 2.5% during the fourth quarter. William Blair Investment Management LLC now owns 380,324 shares of the medical equipment provider's stock worth $34,024,000 after acquiring an additional 9,245 shares during the last quarter. Cibc World Markets Corp acquired a new position in shares of Lantheus during the 4th quarter worth approximately $576,000. First National Advisers LLC grew its position in shares of Lantheus by 4.1% in the fourth quarter. First National Advisers LLC now owns 27,914 shares of the medical equipment provider's stock valued at $2,497,000 after purchasing an additional 1,098 shares in the last quarter. Royce & Associates LP acquired a new stake in shares of Lantheus in the fourth quarter valued at approximately $3,330,000. Finally, Monimus Capital Management LP purchased a new position in Lantheus during the fourth quarter worth approximately $653,000. 99.06% of the stock is owned by hedge funds and other institutional investors.

Lantheus Price Performance

Shares of LNTH stock traded up $1.73 during trading hours on Monday, hitting $99.44. The company had a trading volume of 646,402 shares, compared to its average volume of 935,798. Lantheus Holdings, Inc. has a fifty-two week low of $57.92 and a fifty-two week high of $126.89. The company's fifty day moving average is $92.67 and its 200 day moving average is $96.51. The stock has a market capitalization of $6.81 billion, a PE ratio of 16.55 and a beta of 0.38.

Remove Ads

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The firm had revenue of $391.11 million for the quarter, compared to analysts' expectations of $376.61 million. Equities analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Analyst Ratings Changes

LNTH has been the subject of a number of recent research reports. JMP Securities reaffirmed a "market outperform" rating and issued a $112.00 target price on shares of Lantheus in a research note on Tuesday, January 14th. B. Riley reduced their target price on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a research note on Friday. Truist Financial increased their price target on shares of Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a research note on Thursday, February 27th. Finally, The Goldman Sachs Group began coverage on shares of Lantheus in a research report on Wednesday, December 18th. They set a "buy" rating and a $143.00 price target on the stock. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $129.43.

Insider Transactions at Lantheus

In other Lantheus news, Director Mary Anne Heino sold 53,107 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the transaction, the director now owns 440,399 shares in the company, valued at $41,551,645.65. The trade was a 10.76 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director James H. Thrall sold 1,000 shares of the company's stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the sale, the director now directly owns 33,207 shares in the company, valued at $3,146,695.32. This represents a 2.92 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 64,109 shares of company stock valued at $6,110,806. 1.50% of the stock is currently owned by corporate insiders.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.